Contract Research & Services
Clinical Trials

Clinical Trials News

View news from other Pharmaceutical sectors:
271-285 of 4213 results
Cancer Research UK, Bicycle Therapeutics partner to trial new therapy for advanced solid tumours
Cancer Research UK, Cancer Research Technology (CRT), and Bicycle Therapeutics will collaborate to trial a first-in-class drug for cancers of high unmet need.
Contract Research & Services > Clinical Trials > News
vTv Therapeutics' TTP273 meets primary endpoint in phase 2 study in Type 2 Diabetes
vTv Therapeutics' TTP273, an oral small molecule GLP-1 receptor (GLP-1R) agonist, demonstrated a statistically significant reduction in HbA1c in a Phase 2 study for the treatment of Type 2 diabetes.
Contract Research & Services > Clinical Trials > News
Sage Therapeutics starts phase 2 study of SAGE-217 in movement disorders
By PBR Staff Writer
Clinical-stage biopharmaceutical firm Sage Therapeutics has dosed the first patient in phase 2 proof-of-concept trial of SAGE-217 in Parkinson's disease (PD).
Contract Research & Services > Clinical Trials > News
Novartis’ ribociclib shows significant benefit in advanced breast cancer
By PBR Staff Writer
Additional analyses of a Phase 3 study, evaluating Novartis' LEE011 (ribociclib), in combination with Femara (letrozole), in patients with hormone-receptor-positive, human epidermal growth factor receptor-2-negative (HR+/HER2-) advanced/metastatic breast cancer demonstrated that the combination significantly increased progression-free survival (PFS) compared to letrozole alone.
Contract Research & Services > Clinical Trials > News
Valneva gets approvals to start clinical testing of lyme disease vaccine candidate
Valneva’s vaccine candidate VLA15 against Lyme disease is now moving into clinical testing (phase I) after securing approvals in the US and Europe.
Contract Research & Services > Clinical Trials > News
Horizon Pharma stops development of Actimmune for Friedreich's ataxia
By PBR Staff Writer
Horizon Pharma is discontinuing the development of its interferon gamma-1b protein therapy Actimmume for the Friedreich’s ataxia (FA) indication, after a phase III study did not meet both its primary and secondary endpoints.
Contract Research & Services > Clinical Trials > News
Aclaris starts phase 1 trial for ATI-50001 to treat alopecia totalis and alopecia universalis
Aclaris Therapeutics' investigational new drug (IND) application for ATI-50001, an orally administered investigational Janus Kinase (JAK) inhibitor, for the potential treatment of alopecia totalis and alopecia universalis has cleared the 30-day review period by the US Food and Drug Administration, allowing the company to go ahead with its planned Phase 1 clinical trial
Contract Research & Services > Clinical Trials > News
Cascadian Therapeutics amends HER2CLIMB phase 2 trial of tucatinib
Cascadian Therapeutics announced that after a recent meeting with the US Food and Drug Administration (FDA) and discussions with the Company's external Steering Committee, it has amended the HER2CLIMB Phase 2 clinical trial of tucatinib (also known as ONT-380) by increasing the sample size so that, if successful, the trial could serve as a single pivotal study to support registration.
Contract Research & Services > Clinical Trials > News
Novartis' Zykadia beats chemotherapy in phase III lung cancer study
Novartis has unveiled Zykadia first-line study results demonstrating 16.6 month progression-free survival in patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
AstraZeneca's Tagrisso reduces lung cancer progression by 70% in phase III study
By PBR Staff Writer
A phase 3 clinical trial assessing AstraZeneca's Tagrisso (osimertinib) for the second-line treatment of epidermal growth factor receptor (EGFR) T790M mutation-positive metastatic non-small cell lung cancer (NSCLC) demonstrated a significant treatment benefit.
Contract Research & Services > Clinical Trials > News
Matinas starts dosing in phase 1 study of orally administered aminoglycoside antibiotic MAT2501
Matinas BioPharma has commenced dosing in the Phase 1 clinical study of its lead antibiotic product candidate MAT2501, under development for the treatment of nontuberculous mycobacterium infections (NTM) as an initial indication.
Contract Research & Services > Clinical Trials > News
Pfizer's Bosulif found superior to Gleevec in phase 3 study in type of leukemia
By PBR Staff Writer
Pfizer’s cancer drug Bosulif (bosutinib) was found superior to Novartis' Gleevec (imatinib mesylate) in a phase 3 study for first-line treatment of Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML).
Contract Research & Services > Clinical Trials > News
Shire's VONVENDI meets primary endpoint in controlling bleeding in VWD adults in phase 3 study
A phase 3 clinical trial of Shire's VONVENDI [von Willebrand factor (Recombinant)] to treat bleeds in elective surgical settings for adults with severe von Willebrand disease (VWD) has met primary endpoint.
Contract Research & Services > Clinical Trials > News
Pfizer’s Glasdegib improves OS in AML and MDS patients in phase 2 trial
The new phase 2 results demonstrated that Pfizer's investigational compound Glasdegib improved overall survival (OS) in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
Contract Research & Services > Clinical Trials > News
ACADIA begins phase 2 trial of Nuplazid in major depressive disorder
ACADIA Pharmaceuticals has started a Phase II study dubbed CLARITY to evaluate pimavanserin for adjunctive treatment in patients with major depressive disorder (MDD) who have an inadequate response to first-line therapies for clinical depression.
Contract Research & Services > Clinical Trials > News
271-285 of 4213 results